In 1998, guidance on the use of new drugs for Alzheimer's disease produced by the Standing Medical Advisory Committee in England and endorsed by the National Medical Advisory Committee in Scotland, was issued to all relevant clinicians from the Chief Medical Officer and the Chief Pharmaceutical Officer.